PL2125776T3 - Związki spiro podstawione jako inhibitory angiogenezy - Google Patents
Związki spiro podstawione jako inhibitory angiogenezyInfo
- Publication number
- PL2125776T3 PL2125776T3 PL08730589T PL08730589T PL2125776T3 PL 2125776 T3 PL2125776 T3 PL 2125776T3 PL 08730589 T PL08730589 T PL 08730589T PL 08730589 T PL08730589 T PL 08730589T PL 2125776 T3 PL2125776 T3 PL 2125776T3
- Authority
- PL
- Poland
- Prior art keywords
- angiogenesis inhibitors
- substituted compounds
- spiro substituted
- spiro
- compounds
- Prior art date
Links
- 229940121369 angiogenesis inhibitor Drugs 0.000 title 1
- 239000004037 angiogenesis inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 125000003003 spiro group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89469207P | 2007-03-14 | 2007-03-14 | |
| US94169807P | 2007-06-04 | 2007-06-04 | |
| US12/036,244 US8148532B2 (en) | 2007-03-14 | 2008-02-23 | Spiro substituted compounds as angiogenesis inhibitors |
| EP08730589.2A EP2125776B1 (en) | 2007-03-14 | 2008-02-24 | Spiro substituted compounds as angiogenesis inhibitors |
| PCT/US2008/054816 WO2008112407A1 (en) | 2007-03-14 | 2008-02-24 | Spiro substituted compounds as angiogenesis inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2125776T3 true PL2125776T3 (pl) | 2017-12-29 |
Family
ID=39759893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08730589T PL2125776T3 (pl) | 2007-03-14 | 2008-02-24 | Związki spiro podstawione jako inhibitory angiogenezy |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8148532B2 (pl) |
| EP (1) | EP2125776B1 (pl) |
| JP (1) | JP5522371B2 (pl) |
| KR (1) | KR101514469B1 (pl) |
| CN (4) | CN105837559B (pl) |
| AU (1) | AU2008226666B2 (pl) |
| BR (1) | BRPI0805826B8 (pl) |
| CA (1) | CA2709220C (pl) |
| DK (1) | DK2125776T3 (pl) |
| ES (1) | ES2643619T3 (pl) |
| IL (1) | IL200934A0 (pl) |
| MX (1) | MX2009008953A (pl) |
| NZ (1) | NZ579389A (pl) |
| PL (1) | PL2125776T3 (pl) |
| PT (1) | PT2125776T (pl) |
| WO (1) | WO2008112407A1 (pl) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8163923B2 (en) * | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| US8211911B2 (en) | 2008-08-19 | 2012-07-03 | Guoqing Paul Chen | Compounds as kinase inhibitors |
| CA2740746A1 (en) * | 2008-10-14 | 2010-04-22 | Ning Xi | Compounds comprising a spiro-ring and and methods of use |
| EP2408300B1 (en) * | 2009-03-21 | 2016-05-11 | Sunshine Lake Pharma Co., Ltd. | Amino ester derivatives, salts thereof and methods of use |
| CN103664890B (zh) * | 2010-08-01 | 2016-10-05 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶及制备方法 |
| CN102344438B (zh) * | 2010-08-01 | 2014-02-19 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶及其制备方法 |
| US8664244B2 (en) * | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| WO2012122011A2 (en) | 2011-03-04 | 2012-09-13 | Glaxosmithkline Llc | Amino-quinolines as kinase inhibitors |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| US9695108B2 (en) | 2012-08-23 | 2017-07-04 | Georgetown University | Compounds and methods of use thereof for treating tumors |
| TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基－喹啉類 |
| TWI592417B (zh) | 2012-09-13 | 2017-07-21 | 葛蘭素史克智慧財產發展有限公司 | 胺基喹唑啉激酶抑制劑之前藥 |
| MX2015008543A (es) * | 2013-01-18 | 2015-11-16 | Advenchen Pharmaceuticals Llc | Proceso para preparar el agente antitumoral 6-(7-((1-aminoaciclopr opil)metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1-naftamida y su cristalino. |
| WO2014127335A1 (en) * | 2013-02-15 | 2014-08-21 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| CA2900652C (en) | 2013-02-15 | 2021-05-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| CN107915751A (zh) * | 2013-02-20 | 2018-04-17 | 卡拉制药公司 | 治疗性化合物和其用途 |
| TWI630203B (zh) | 2013-02-21 | 2018-07-21 | 葛蘭素史克智慧財產發展有限公司 | 做為激酶抑制劑的喹唑啉類 |
| CN105213394B (zh) * | 2014-06-06 | 2019-04-09 | 正大天晴药业集团股份有限公司 | 具有抗肿瘤活性的喹啉衍生物 |
| CN105311030B (zh) * | 2014-06-06 | 2020-03-24 | 正大天晴药业集团股份有限公司 | 用于抗肿瘤的螺取代化合物 |
| CN105311029A (zh) * | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 抗肿瘤活性的喹啉衍生物 |
| CN105722840B (zh) | 2014-07-14 | 2018-01-05 | 杭州爱德程医药科技有限公司 | 作为PI3K、mTOR抑制剂的稠合喹啉化合物 |
| WO2016091167A1 (zh) * | 2014-12-09 | 2016-06-16 | 正大天晴药业集团股份有限公司 | 抗肺鳞癌的喹啉衍生物 |
| WO2016091168A1 (zh) * | 2014-12-09 | 2016-06-16 | 正大天晴药业集团股份有限公司 | 抗非小细胞肺癌的喹啉衍生物 |
| CN114831988A (zh) * | 2014-12-09 | 2022-08-02 | 正大天晴药业集团股份有限公司 | 治疗非小细胞肺癌的喹啉衍生物 |
| US9751859B2 (en) * | 2015-05-04 | 2017-09-05 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
| CN114805351B (zh) | 2015-07-11 | 2023-05-09 | 南京爱德程医药科技有限公司 | 作为pi3k/mtor抑制剂的带有酰胺基的吡啶基取代的稠合喹啉化合物 |
| WO2017035114A1 (en) | 2015-08-25 | 2017-03-02 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as cb-1 inverse agonists |
| US20190112317A1 (en) | 2015-10-05 | 2019-04-18 | The Trustees Of Columbia University In The City Of New York | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies |
| WO2017118401A1 (zh) * | 2016-01-08 | 2017-07-13 | 正大天晴药业集团股份有限公司 | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 |
| CN107296811B (zh) * | 2016-04-15 | 2022-12-30 | 正大天晴药业集团股份有限公司 | 一种用于治疗胃癌的喹啉衍生物 |
| CN107778288B (zh) * | 2016-08-26 | 2020-07-28 | 正大天晴药业集团股份有限公司 | 一种喹啉衍生物的杂质及其制备方法和用途 |
| CN107778290B (zh) * | 2016-08-30 | 2020-07-24 | 正大天晴药业集团股份有限公司 | 一种喹啉衍生物的杂质及其制备方法 |
| CN110650741A (zh) * | 2017-05-26 | 2020-01-03 | 正大天晴药业集团股份有限公司 | 用于治疗结直肠癌的喹啉衍生物 |
| CN109422731A (zh) * | 2017-08-24 | 2019-03-05 | 正大天晴药业集团股份有限公司 | 氘代喹啉衍生物 |
| WO2019052520A1 (zh) | 2017-09-15 | 2019-03-21 | 正大天晴药业集团股份有限公司 | 用于治疗神经内分泌肿瘤的喹啉衍生物 |
| CN107970241B (zh) | 2018-01-22 | 2020-05-22 | 正大天晴药业集团股份有限公司 | 一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用 |
| CN111630045A (zh) * | 2018-02-11 | 2020-09-04 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶 |
| JP2021517162A (ja) | 2018-03-02 | 2021-07-15 | チア タイ チオギン ファーマスーチカル グループ コーポレイテッド，リミテッド | Ｃ−ｍｅｔキナーゼ阻害剤としての化合物の結晶及びその調製方法及びその使用 |
| US11419862B2 (en) | 2018-03-14 | 2022-08-23 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative for treatment of nasopharyngeal carcinoma |
| US11554115B2 (en) * | 2018-03-14 | 2023-01-17 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative for treatment of triple-negative breast cancer |
| CN111757736B (zh) * | 2018-03-14 | 2022-10-18 | 正大天晴药业集团股份有限公司 | 治疗鼻咽癌的喹啉衍生物 |
| CN110339195A (zh) * | 2018-04-02 | 2019-10-18 | 正大天晴药业集团股份有限公司 | 用于治疗胆管癌的喹啉衍生物 |
| CN110357856B (zh) * | 2018-04-09 | 2021-02-26 | 新发药业有限公司 | 一种盐酸安罗替尼中间体及盐酸安罗替尼的制备方法 |
| CN110483392A (zh) * | 2018-05-14 | 2019-11-22 | 上海海和药物研究开发有限公司 | 合成n-保护的喹啉-7-基氧基甲基环丙基胺衍生物的方法及合成中间体 |
| CN112105361A (zh) * | 2018-05-22 | 2020-12-18 | 正大天晴药业集团股份有限公司 | 用于治疗非小细胞肺癌的喹啉衍生物 |
| CN110577546B (zh) * | 2018-06-08 | 2021-09-07 | 江苏威凯尔医药科技有限公司 | Vegfr抑制剂及其制备方法和应用 |
| WO2019233458A1 (zh) * | 2018-06-08 | 2019-12-12 | 江苏威凯尔医药科技有限公司 | Vegfr抑制剂及其制备方法和应用 |
| CN112368273A (zh) * | 2018-06-25 | 2021-02-12 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的晶习及其结晶粉末的制备方法 |
| WO2020015703A1 (zh) | 2018-07-18 | 2020-01-23 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与抗体的药物组合 |
| CN115850237B (zh) * | 2018-07-24 | 2025-03-28 | 正大天晴药业集团股份有限公司 | 一种吲哚衍生物的合成方法 |
| CN108864050B (zh) * | 2018-07-25 | 2019-12-10 | 上海博璞诺科技发展有限公司 | 一种合成安罗替尼及其盐酸盐的方法 |
| CN112584834B (zh) * | 2018-08-06 | 2022-04-12 | 正大天晴药业集团股份有限公司 | 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物 |
| WO2020057403A1 (zh) * | 2018-09-18 | 2020-03-26 | 北京越之康泰生物医药科技有限公司 | 吲哚衍生物及其在医药上的应用 |
| WO2020057539A1 (zh) | 2018-09-18 | 2020-03-26 | 正大天晴药业集团股份有限公司 | 用于治疗小细胞肺癌的喹啉衍生物 |
| CN109705093A (zh) * | 2018-12-29 | 2019-05-03 | 正大天晴药业集团股份有限公司 | 喹啉衍生物及其制备方法和用途 |
| JP7582952B2 (ja) | 2019-01-25 | 2024-11-13 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 腫瘍治療用の併用医薬組成物 |
| CN109748904A (zh) | 2019-01-31 | 2019-05-14 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶 |
| CN111617243B (zh) * | 2019-02-28 | 2023-12-19 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与抗体的药物组合 |
| CN111643502A (zh) * | 2019-03-04 | 2020-09-11 | 正大天晴药业集团股份有限公司 | 喹啉衍生物联合化疗药物用于治疗非小细胞肺癌 |
| CN111643503A (zh) * | 2019-03-04 | 2020-09-11 | 正大天晴药业集团股份有限公司 | 用于治疗非小细胞肺癌的喹啉衍生物 |
| CN111714498A (zh) * | 2019-03-20 | 2020-09-29 | 正大天晴药业集团股份有限公司 | 用于治疗卵巢癌的喹啉衍生物 |
| WO2020211860A1 (zh) | 2019-04-19 | 2020-10-22 | 正大天晴药业集团股份有限公司 | 用于治疗尤因肉瘤的喹啉类化合物或其药学上可接受的盐 |
| CN111840289A (zh) * | 2019-04-28 | 2020-10-30 | 正大天晴药业集团股份有限公司 | 用于治疗骨巨细胞瘤的喹啉类化合物或其药学上可接受的盐 |
| WO2020228657A1 (zh) | 2019-05-10 | 2020-11-19 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与抗体联合治疗软组织肉瘤 |
| JP7571053B2 (ja) | 2019-05-10 | 2024-10-22 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 軟部肉腫の併用療法用キノリン誘導体 |
| EP3973963A4 (en) * | 2019-05-23 | 2023-06-14 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivatives for treatment of head and neck cancer |
| CN112300286A (zh) | 2019-08-02 | 2021-02-02 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体及其用途 |
| KR20220062503A (ko) | 2019-08-02 | 2022-05-17 | 씨티티큐-아케소 (상하이) 바이오메드. 테크. 컴퍼니, 리미티드 | 항-pd-1 항체 및 이의 약제학적 용도 |
| CN114667159B (zh) | 2019-11-04 | 2024-04-26 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与pd-1单抗的药物组合 |
| CN114929225B (zh) * | 2020-01-19 | 2024-06-28 | 正大天晴药业集团股份有限公司 | 用于治疗类风湿性关节炎的喹啉衍生物 |
| CN113262223A (zh) * | 2020-02-17 | 2021-08-17 | 上海交通大学医学院 | 安罗替尼及其药学上可接受的盐在制备治疗多发性骨髓瘤药物中的应用 |
| CN112358469A (zh) * | 2020-03-18 | 2021-02-12 | 北京康辰药业股份有限公司 | 血管生成抑制剂、其制备方法及其应用 |
| CN112912373B (zh) * | 2020-03-18 | 2022-08-23 | 北京康辰药业股份有限公司 | 血管生成抑制剂、其制备方法和应用 |
| CN111888358A (zh) * | 2020-08-24 | 2020-11-06 | 天津济坤医药科技有限公司 | 安罗替尼在制备用于治疗肝纤维化疾病的药物中的应用 |
| KR20240115979A (ko) | 2021-11-08 | 2024-07-26 | 프로젠토스 테라퓨틱스, 인크. | 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도 |
| EP4673223A1 (en) | 2023-02-27 | 2026-01-07 | Assia Chemical Industries Ltd. | Solid state forms of anlotinib and process for preparation thereof |
| CN120154618B (zh) * | 2025-05-15 | 2025-11-18 | 正大天晴药业集团股份有限公司 | 格索雷塞用于治疗肺癌的用途或其药物组合物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4227989A1 (de) | 1992-08-21 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel |
| WO1997017329A1 (en) | 1995-11-07 | 1997-05-15 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BRPI0017548B8 (pt) | 1999-02-10 | 2023-05-02 | Astrazeneca Ab | Composto |
| EP1415987B1 (en) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
| CN1688549A (zh) * | 2002-08-23 | 2005-10-26 | 麒麟麦酒株式会社 | 具有TGFβ抑制活性的化合物和含所述化合物的药用组合物 |
| US7129252B2 (en) | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
| CA2536788A1 (en) | 2003-08-29 | 2005-03-10 | Pfizer Inc. | Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents |
| JP2007510708A (ja) * | 2003-11-06 | 2007-04-26 | ファイザー・プロダクツ・インク | 癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ |
| JP4503022B2 (ja) * | 2003-12-23 | 2010-07-14 | ファイザー・インク | 新規キノリン誘導体 |
| CA2553433A1 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc. | Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer |
| JP4932495B2 (ja) | 2004-01-23 | 2012-05-16 | アムゲン インコーポレイテッド | 化合物及び使用方法 |
| WO2005080377A1 (ja) | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
| WO2005097134A2 (en) | 2004-03-31 | 2005-10-20 | The Scripps Research Institute | Quinazoline based protein kinase inhibitors |
| WO2005114219A2 (en) | 2004-05-20 | 2005-12-01 | Wyeth | Assays to identify irreversibly binding inhibitors of receptor tyrosine kinases |
| KR100735639B1 (ko) * | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| JP2008537748A (ja) | 2005-04-06 | 2008-09-25 | エクセリクシス、インコーポレイテッド | ｃ−Ｍｅｔモジュレーター及び使用方法 |
| US8163923B2 (en) * | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
-
2008
- 2008-02-23 US US12/036,244 patent/US8148532B2/en active Active
- 2008-02-24 PT PT87305892T patent/PT2125776T/pt unknown
- 2008-02-24 CN CN201610147579.3A patent/CN105837559B/zh active Active
- 2008-02-24 CN CN200880007358XA patent/CN101809012B/zh active Active
- 2008-02-24 ES ES08730589.2T patent/ES2643619T3/es active Active
- 2008-02-24 BR BRPI0805826A patent/BRPI0805826B8/pt active IP Right Grant
- 2008-02-24 CA CA2709220A patent/CA2709220C/en active Active
- 2008-02-24 KR KR1020097016377A patent/KR101514469B1/ko active Active
- 2008-02-24 EP EP08730589.2A patent/EP2125776B1/en active Active
- 2008-02-24 NZ NZ579389A patent/NZ579389A/en not_active IP Right Cessation
- 2008-02-24 AU AU2008226666A patent/AU2008226666B2/en not_active Ceased
- 2008-02-24 PL PL08730589T patent/PL2125776T3/pl unknown
- 2008-02-24 WO PCT/US2008/054816 patent/WO2008112407A1/en not_active Ceased
- 2008-02-24 MX MX2009008953A patent/MX2009008953A/es active IP Right Grant
- 2008-02-24 CN CN201310454104.5A patent/CN103467454B/zh active Active
- 2008-02-24 JP JP2009553672A patent/JP5522371B2/ja active Active
- 2008-02-24 DK DK08730589.2T patent/DK2125776T3/en active
- 2008-02-24 CN CN201310454117.2A patent/CN103483319B/zh active Active
-
2009
- 2009-09-14 IL IL200934A patent/IL200934A0/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2709220C (en) | 2016-07-19 |
| DK2125776T3 (en) | 2017-10-23 |
| CN103483319A (zh) | 2014-01-01 |
| PT2125776T (pt) | 2017-10-04 |
| CN103483319B (zh) | 2015-10-14 |
| EP2125776B1 (en) | 2017-07-05 |
| EP2125776A4 (en) | 2011-06-22 |
| JP5522371B2 (ja) | 2014-06-18 |
| IL200934A0 (en) | 2010-05-17 |
| ES2643619T3 (es) | 2017-11-23 |
| NZ579389A (en) | 2012-04-27 |
| BRPI0805826B8 (pt) | 2021-05-25 |
| CN105837559B (zh) | 2019-11-29 |
| US8148532B2 (en) | 2012-04-03 |
| CN105837559A (zh) | 2016-08-10 |
| CA2709220A1 (en) | 2008-09-18 |
| AU2008226666A1 (en) | 2008-09-18 |
| CN103467454B (zh) | 2016-05-04 |
| CN103467454A (zh) | 2013-12-25 |
| BRPI0805826A2 (pt) | 2011-08-30 |
| AU2008226666B2 (en) | 2013-10-03 |
| EP2125776A1 (en) | 2009-12-02 |
| WO2008112407A1 (en) | 2008-09-18 |
| KR101514469B1 (ko) | 2015-04-22 |
| CN101809012A (zh) | 2010-08-18 |
| MX2009008953A (es) | 2009-12-18 |
| CN101809012B (zh) | 2013-11-27 |
| US20080227811A1 (en) | 2008-09-18 |
| JP2010521473A (ja) | 2010-06-24 |
| KR20090129985A (ko) | 2009-12-17 |
| BRPI0805826B1 (pt) | 2021-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL200934A0 (en) | Spiro substituted compounds as angiogenesis inhibitors | |
| IL200854A0 (en) | Spiro substituted compounds as angiogenesis inhibitors | |
| AP2010005163A0 (en) | Substituted bicyclolactam compounds | |
| ZA201107772B (en) | Substituted spiro-amide compounds | |
| IL215615A0 (en) | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750 | |
| EP2146745A4 (en) | NOVEL CONNECTIONS | |
| EP2152081A4 (en) | NEW CONNECTIONS | |
| IL231955A0 (en) | Tetracycline compounds are substituted at the 7c position with fluorine | |
| GB0705882D0 (en) | Novel compounds | |
| IL210573A0 (en) | Compounds as kinase inhibitors | |
| IL220701A0 (en) | Tricyclic compounds for use as kinase inhibitors | |
| ZA201205726B (en) | Substituted naphthalenyl-pyrimidine compounds | |
| GB0705803D0 (en) | Novel compounds | |
| GB0703973D0 (en) | Novel compounds | |
| IL210015A0 (en) | Substituted cyclohexylidene-ethylidene-octahydro-indene compounds | |
| GB0706030D0 (en) | Novel compounds | |
| GB0703402D0 (en) | Novel compounds | |
| GB0703631D0 (en) | Novel compounds | |
| GB0700077D0 (en) | Novel compounds | |
| GB0704324D0 (en) | Novel compounds | |
| GB0700078D0 (en) | Novel compounds | |
| GB0700991D0 (en) | Novel compounds | |
| GB0701638D0 (en) | Novel compounds | |
| GB0704088D0 (en) | Novel compounds | |
| GB0703397D0 (en) | Novel compounds |